{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T12:22:20Z","timestamp":1789129340496,"version":"build-2803163510"},"reference-count":61,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T00:00:00Z","timestamp":1718668800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.neuropharm.2024.110037","type":"journal-article","created":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T16:43:58Z","timestamp":1718210638000},"page":"110037","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Navacaprant, a novel and selective kappa opioid receptor antagonist, has no agonist properties implicated in opioid-related abuse"],"prefix":"10.1016","volume":"257","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6545-5020","authenticated-orcid":false,"given":"Filomene G.","family":"Morrison","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lori Jean","family":"Van Orden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2139-9092","authenticated-orcid":false,"given":"Karla","family":"Zeitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1396-5568","authenticated-orcid":false,"given":"Eloise J.","family":"Kuijer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon L.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6128-9632","authenticated-orcid":false,"given":"David J.","family":"Heal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanya L.","family":"Wallace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2024.110037_bib1","first-page":"2254","article-title":"Nalmefene induced elevation in serum prolactin in normal human volunteers: partial kappa opioid agonist activity?","volume":"30","author":"Bart","year":"2005","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2024.110037_bib2","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1007\/s00213-005-0167-4","article-title":"Differential effects of the novel kappa opioid receptor antagonist, JDTic, on reinstatement of cocaine-seeking induced by footshock stressors vs cocaine primes and its antidepressant-like effects in rats","volume":"183","author":"Beardsley","year":"2005","journal-title":"Psychopharmacology (Berl)."},{"key":"10.1016\/j.neuropharm.2024.110037_bib4","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1210\/edrv.22.6.0451","article-title":"Dopamine as a prolactin (PRL) inhibitor","volume":"22","author":"Ben-Jonathan","year":"2001","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.neuropharm.2024.110037_bib5","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1097\/HRP.0000000000000242","article-title":"Novel targets to treat depression: opioid-based therapeutics","volume":"28","author":"Browne","year":"2020","journal-title":"Harv. Rev. Psychiatr."},{"key":"10.1016\/j.neuropharm.2024.110037_bib7","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S0014-2999(01)01121-9","article-title":"Kappa-opioid receptor agonist-induced prolactin release in primates is blocked by dopamine D(2)-like receptor agonists","volume":"423","author":"Butelman","year":"2001","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2024.110037_bib8","doi-asserted-by":"crossref","first-page":"253","DOI":"10.3389\/fphar.2014.00253","article-title":"Does the kappa opioid receptor system contribute to pain aversion?","volume":"5","author":"Cahill","year":"2014","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.neuropharm.2024.110037_bib9","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.ejphar.2007.05.007","article-title":"Reinstatement of cocaine place-conditioning prevented by the peptide kappa-opioid receptor antagonist arodyn","volume":"569","author":"Carey","year":"2007","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2024.110037_bib10","doi-asserted-by":"crossref","first-page":"2987","DOI":"10.1038\/nprot.2007.441","article-title":"Intracranial self-stimulation (ICSS) in rodents to study the neurobiology of motivation","volume":"2","author":"Carlezon","year":"2007","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.neuropharm.2024.110037_bib11","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1124\/jpet.105.092304","article-title":"Depressive-like effects of the kappa-opioid receptor agonist salvinorin A on behavior and neurochemistry in rats","volume":"316","author":"Carlezon","year":"2006","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2024.110037_bib12","doi-asserted-by":"crossref","first-page":"627","DOI":"10.2307\/4594256","article-title":"A critical review of pentazocine abuse","volume":"86","author":"Chambers","year":"1971","journal-title":"HSMHA Health Rep."},{"key":"10.1016\/j.neuropharm.2024.110037_bib13","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/FBP.0000000000000080","article-title":"Drug withdrawal conceptualized as a stressor","volume":"25","author":"Chartoff","year":"2014","journal-title":"Behav. Pharmacol."},{"key":"10.1016\/j.neuropharm.2024.110037_bib14","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1126\/science.6120570","article-title":"Dynorphin is a specific endogenous ligand of the kappa opioid receptor","volume":"215","author":"Chavkin","year":"1982","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2024.110037_bib15","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/0014-2999(95)00552-8","article-title":"(\u2212)-Pentazocine analgesia in mice: interactions with a \u03c3 receptor system","volume":"294","author":"Chien","year":"1995","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2024.110037_bib16","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/0006-8993(87)90101-6","article-title":"Subtraction autoradiography of opiate receptor subtypes in human brain","volume":"418","author":"Cross","year":"1987","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2024.110037_bib17","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/s41583-018-0028-x","article-title":"Opioid receptors: drivers to addiction?","volume":"19","author":"Darcq","year":"2018","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.neuropharm.2024.110037_bib18","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1111\/j.1749-6632.1986.tb23629.x","article-title":"Preferential stimulation of dopamine release in the nucleus accumbens by opiates, alcohol, and barbiturates: studies with transcerebral dialysis in freely moving rats","volume":"473","author":"Di Chiara","year":"1986","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.neuropharm.2024.110037_bib19","doi-asserted-by":"crossref","first-page":"5274","DOI":"10.1073\/pnas.85.14.5274","article-title":"Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats","volume":"85","author":"Di Chiara","year":"1988","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"key":"10.1016\/j.neuropharm.2024.110037_bib20","first-page":"193","article-title":"Kappa agonist-induced reduction in dopamine release: site of action and tolerance","volume":"78","author":"Donzanti","year":"1992","journal-title":"Res. Commun. Chem. Pathol. Pharmacol."},{"key":"10.1016\/j.neuropharm.2024.110037_bib21","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s00213-010-1836-5","article-title":"Depressive-like effects of the kappa opioid receptor agonist salvinorin A are associated with decreased phasic dopamine release in the nucleus accumbens","volume":"210","author":"Ebner","year":"2010","journal-title":"Psychopharmacology (Berl)."},{"key":"10.1016\/j.neuropharm.2024.110037_bib22","first-page":"18","article-title":"Double-blind, placebo-controlled, proof-of-concept trial of a kappa-selective opioid receptor antagonist augmentation in treatment-resistant depression","volume":"32","author":"Fava","year":"2020","journal-title":"Ann. Clin. Psychiatr."},{"key":"10.1016\/j.neuropharm.2024.110037_bib23","first-page":"1253","article-title":"Butorphanol-mediated antinociception in mice: partial agonist effects and mu receptor involvement","volume":"282","author":"Garner","year":"1997","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2024.110037_bib24","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1021\/acs.jmedchem.8b01679","article-title":"Design and synthesis of a novel and selective kappa opioid receptor (KOR) antagonist (BTRX-335140)","volume":"62","author":"Guerrero","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.neuropharm.2024.110037_bib25","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.neuropharm.2018.01.049","article-title":"Evaluating the abuse potential of psychedelic drugs as part of the safety pharmacology assessment for medical use in humans","volume":"142","author":"Heal","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2024.110037_bib26","doi-asserted-by":"crossref","first-page":"473","DOI":"10.2165\/00003495-197816060-00001","article-title":"Butorphanol: a review of its pharmacological properties and therapeutic efficacy","volume":"16","author":"Heel","year":"1978","journal-title":"Drugs"},{"key":"10.1016\/j.neuropharm.2024.110037_bib27","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/0304-3940(87)90591-X","article-title":"Agonist action of the agonist\/antagonist analgesic butorphanol on dopamine metabolism in the nucleus accumbens of the rat","volume":"77","author":"Iyengar","year":"1987","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.neuropharm.2024.110037_bib28","doi-asserted-by":"crossref","first-page":"3715","DOI":"10.1007\/s00213-020-05649-y","article-title":"The kappa opioid receptor antagonist aticaprant reverses behavioral effects from unpredictable chronic mild stress in male mice","volume":"237","author":"Jacobson","year":"2020","journal-title":"Psychopharmacology (Berl)."},{"key":"10.1016\/j.neuropharm.2024.110037_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.brainres.2020.146742","article-title":"Dynorphin and its role in alcohol use disorder","volume":"1735","author":"Karkhanis","year":"2020","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2024.110037_bib30","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.brainres.2009.09.074","article-title":"Dynorphin, stress, and depression","volume":"1314","author":"Knoll","year":"2010","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2024.110037_bib31","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/0014-2999(96)00520-1","article-title":"Peripheral kappa 1-opioid receptor-mediated analgesia in mice","volume":"310","author":"Kolesnikov","year":"1996","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2024.110037_bib32","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0165-6147(92)90060-J","article-title":"Drugs of abuse: anatomy, pharmacology and function of reward pathways","volume":"13","author":"Koob","year":"1992","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.neuropharm.2024.110037_bib33","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1038\/s41591-020-0806-7","article-title":"A randomized proof-of-mechanism trial applying the 'fast-fail' approach to evaluating \u03ba-opioid antagonism as a treatment for anhedonia","volume":"26","author":"Krystal","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.neuropharm.2024.110037_bib34","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1038\/npp.2017.120","article-title":"Role of \u03ba-opioid receptors in the bed nucleus of stria terminalis in reinstatement of alcohol seeking","volume":"43","author":"L\u00ea","year":"2018","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2024.110037_bib35","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s00213-012-2912-9","article-title":"Dose-related effects of salvinorin A in humans: dissociative, hallucinogenic, and memory effects","volume":"226","author":"MacLean","year":"2013","journal-title":"Psychopharmacology (Berl)."},{"key":"10.1016\/j.neuropharm.2024.110037_bib36","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/0304-3940(94)90559-2","article-title":"U50,488, a kappa opioid receptor agonist, attenuates cocaine-induced increases in extracellular dopamine in the nucleus accumbens of rats","volume":"181","author":"Maisonneuve","year":"1994","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.neuropharm.2024.110037_bib37","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1006\/mcne.1994.1015","article-title":"Kappa 1 receptor mRNA distribution in the rat CNS: comparison to kappa receptor binding and prodynorphin mRNA","volume":"5","author":"Mansour","year":"1994","journal-title":"Mol. Cell. Neurosci."},{"key":"10.1016\/j.neuropharm.2024.110037_bib38","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0232864","article-title":"Differential effects of novel kappa opioid receptor antagonists on dopamine neurons using acute brain slice electrophysiology","volume":"15","author":"Margolis","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.neuropharm.2024.110037_bib39","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1186\/s12889-021-10497-2","article-title":"Take-home naloxone programs for suspected opioid overdose in community settings: a scoping umbrella review","volume":"21","author":"Moustaqim-Barrette","year":"2021","journal-title":"BMC Publ. Health"},{"key":"10.1016\/j.neuropharm.2024.110037_bib40","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1007\/s00213-004-1878-7","article-title":"Effects of the kappa opioid agonist U50,488 and the kappa opioid antagonist nor-binaltorphimine on choice between cocaine and food in rhesus monkeys","volume":"176","author":"Negus","year":"2004","journal-title":"Psychopharmacology (Berl)."},{"key":"10.1016\/j.neuropharm.2024.110037_bib41","first-page":"515","article-title":"Effects of butorphanol and its metabolites on the levels of monoamine and their metabolites in the rat brain. Japan","volume":"39","author":"Niwa","year":"1985","journal-title":"J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2024.110037_bib42","doi-asserted-by":"crossref","first-page":"9937","DOI":"10.1523\/JNEUROSCI.0953-16.2016","article-title":"Stress-induced reinstatement of nicotine preference requires dynorphin\/kappa opioid activity in the basolateral amygdala","volume":"36","author":"Nygard","year":"2016","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2024.110037_bib43","article-title":"An investigation of the reinforcing potential of PN6047 by conditioned place preference testing in rats","author":"Palandri","year":"2019","journal-title":"College on Problems of Drug Dependence (CPDD) Meeting"},{"key":"10.1016\/j.neuropharm.2024.110037_bib44","series-title":"The Rat Brain in Stereotaxic Coordinates","author":"Paxinos","year":"2006"},{"key":"10.1016\/j.neuropharm.2024.110037_bib45","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/0376-8716(87)90008-1","article-title":"Clinical observations of agonist-antagonist analgesic dependence","volume":"20","author":"Peachey","year":"1987","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.neuropharm.2024.110037_bib46","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1126\/science.3016896","article-title":"Psychotomimesis mediated by kappa opiate receptors","volume":"233","author":"Pfeiffer","year":"1986","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2024.110037_bib47","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.neuropharm.2013.09.021","article-title":"LY2456302 is a novel, potent, orally-bioavailable small molecule kappa-selective antagonist with activity in animal models predictive of efficacy in mood and addictive disorders","volume":"77","author":"Rorick-Kehn","year":"2014","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2024.110037_bib48","doi-asserted-by":"crossref","first-page":"17582","DOI":"10.1523\/JNEUROSCI.3220-12.2012","article-title":"Stress produces aversion and potentiates cocaine reward by releasing endogenous dynorphins in the ventral striatum to locally stimulate serotonin reuptake","volume":"32","author":"Schindler","year":"2012","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2024.110037_bib49","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/0028-3908(76)90037-X","article-title":"Antinociceptive activity of narcotic agonist and partial agonist analgesics and other agents in the tail-immersion test in mice and rats","volume":"15","author":"Sewell","year":"1976","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2024.110037_bib50","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1111\/j.1471-4159.1990.tb04963.x","article-title":"The effects of opioid peptides on dopamine release in the nucleus accumbens: an in vivo microdialysis study","volume":"55","author":"Spanagel","year":"1990","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neuropharm.2024.110037_bib51","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.brainres.2018.09.023","article-title":"Dynorphin\/kappa-opioid receptor control of dopamine dynamics: implications for negative affective states and psychiatric disorders","volume":"1713","author":"Tejeda","year":"2019","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2024.110037_bib52","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s00213-003-1680-y","article-title":"Effects of kappa-opioid receptor ligands on intracranial self-stimulation in rats","volume":"172","author":"Todtenkopf","year":"2004","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neuropharm.2024.110037_bib53","article-title":"FDA approves first over-the-counter naloxone nasal spray","year":"2023","journal-title":"US Food and Drug Administration"},{"key":"10.1016\/j.neuropharm.2024.110037_bib54","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.1038\/s41386-018-0225-3","article-title":"Untangling the complexity of opioid receptor function","volume":"43","author":"Valentino","year":"2018","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2024.110037_bib55","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1517\/14740338.6.2.125","article-title":"Naloxone treatment in opioid addiction: the risks and benefits","volume":"6","author":"Van Dorp","year":"2007","journal-title":"Expet Opin. Drug Saf."},{"key":"10.1016\/j.neuropharm.2024.110037_bib56","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s00213-013-3195-5","article-title":"Role of kappa-opioid receptors in stress and anxiety-related behavior","volume":"229","author":"Van\u2019t Veer","year":"2013","journal-title":"Psychopharmacology (Berl)."},{"key":"10.1016\/j.neuropharm.2024.110037_bib57","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.cell.2015.07.046","article-title":"The brain on drugs: from reward to addiction","volume":"162","author":"Volkow","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.neuropharm.2024.110037_bib58","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1007\/BF00995381","article-title":"Simultaneous measurement of biogenic amines and their metabolites in rat brain regions after acute administration of and abrupt withdrawal from butorphanol or morphine","volume":"20","author":"Wakabayashi","year":"1995","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.neuropharm.2024.110037_bib59","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/sj.npp.1301438","article-title":"Pharmacological evidence for a motivational role of kappa-opioid systems in ethanol dependence","volume":"33","author":"Walker","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2024.110037_bib60","doi-asserted-by":"crossref","DOI":"10.1016\/j.ynstr.2022.100493","article-title":"Kappa opioid receptor antagonism protects working memory performance from mild stress exposure in Rhesus macaques","volume":"21","author":"Wallace","year":"2022","journal-title":"Neurobiol. Stress."},{"key":"10.1016\/j.neuropharm.2024.110037_bib61","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1177\/0333102417702120","article-title":"Kappa opioid receptor antagonists: a possible new class of therapeutics for migraine prevention","volume":"8","author":"Xie","year":"2017","journal-title":"Cephalalgia"},{"key":"10.1016\/j.neuropharm.2024.110037_bib62","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/0014-2999(94)00451-X","article-title":"Comparative effects of selective kappa-opioid receptor agonists on dopamine levels in the dorsal caudate of freely moving rats","volume":"264","author":"Zaratin","year":"1994","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2024.110037_bib63","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1007\/s00213-003-1716-3","article-title":"Effect of the kappa opioid agonist R-84760 on cocaine-induced increases in striatal dopamine levels and cocaine-induced place preference in C57BL\/6J mice","volume":"173","author":"Zhang","year":"2004","journal-title":"Psychopharmacology (Berl)."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390824002065?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390824002065?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T22:11:55Z","timestamp":1723587115000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390824002065"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":61,"alternative-id":["S0028390824002065"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2024.110037","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Navacaprant, a novel and selective kappa opioid receptor antagonist, has no agonist properties implicated in opioid-related abuse","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2024.110037","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"110037"}}